F-Star GmbH, an antibody discovery company, has changed its top management and expanded its operations in Cambridge, UK in preparation for the advance of its bispecific antibody platform to the clinic. CEO Kevin FitzGerald is stepping down. ---Subscribe to MedNous to access this article--- Company News